“In the U.S. dermatology and cosmeceutical space, there is strong demand for clinically supported alternatives to traditional depigmentation agents such as hydroquinone. Tonasulike-D is particularly interesting because it combines solid clinical data and is easy to formulate into premium skincare lines, including pre- and post-procedure care,” shared Dr. Michael Gold, renowned Dermatologist recently appointed as Kokuma’s Scientific Advisor.
Clinical evaluation across skin types III–V showed consistent improvements in pigmentation and brightness, with visible results from Day 21 and continued progress over 12 weeks. All participants demonstrated improvement by week 8. Notably, results showed up to a +24% increase in brightness (ITA) on darker skin tones, reinforcing its relevance for inclusive pigmentation care. These concerns remain among the most common dermatological conditions in the United States, particularly where melasma and post-inflammatory Hyperpigmentation occurs. Alongside increased focus on efficacy across all skin tones, consumers are looking for compatibility with dermatology procedures.
Tonasulike-D addresses this need through a multi-pathway mechanism, targeting melanogenesis and melanosome transfer rather than relying solely on tyrosinase inhibition. The ingredient is odorless, white, stable, and easy to formulate, enabling use across facial care, body care, and pre- and post-procedure skincare.
Tonasulike-D is ready for integration into US commercial formulations, supporting all brands or formulators developing next-gen depigmenting solutions backed by clinical evidence.
